iNtRON Biotechnology | July 12, 2022
iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients.
A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes after treatment was confirmed from all of the tested strains. In particular, even though majority of the tested strains are resistant strains to the commonly used antibiotics such as Metronidazole, Vancomycin, and Rifaximin, CDL200 showed very potent and rapid bactericidal activity.
CDL200 is an endolysin-based novel biological drug candidate for the treatment of Clostridioides difficile infection, a hard-to-treat and recurrent bowel diseases. CDL200 has innovative drug properties that can eradicate bacteria much faster than the conventional antibiotics in the market, and also can be used for the infection caused by antibiotic-resistant bacteria and/or highly virulent bacteria.
CDI patient population has been increasing globally and resulting in high mortality rate due to resistance to the existing antibiotics and serious complications such as toxic megacolon, sepsis, and intestinal perforation. Although there is growing interest in refractory CDI that does not respond well to primary treatment, there are only few studies on effective treatment yet. The more serious problem is the frequency of recurrent CDI is increasing, since the risk of subsequent recurrence is over 45% in patients who have had at least one recurrence.
The conventional treatment based on Metronidazole and Vancomycin is not effective for CDI with severe intractability and repeating recurrence. And the recently attempted FMT (fecal microbiota transplantation), that is, the treatment of administering donor feces to the patient's intestinal tract, has advantages such as not suppressing the intestinal flora and not creating resistant strains, but the treatment brings objection to the general public and is limited in that there is a possibility that other pathogens from the donor may be transmitted.
The mortality rate of CDI was about 3-4% in the past, but due to intensification of antibiotic-resistant bacteria and the emergence of highly virulent strain (NAP1/027), the recent mortality rate has been rapidly increased to over 10%, which makes global awareness growing.
Dr. KANG, Sang Hyeon, CTO of iNtRON, said, "We have a number of new endolysin pipelines under the development utilizing our unique itLysin® technology for the serious infection that the development of effective therapeutic agents are urgently needed."
"Based on the development experience of SAL200, we will strive to enhance the value of our rich itLysin® pipelines and will continue to secure global competitiveness in the endolysin field."
Mr. YOON, Kyung Won, CEO of iNtRON
CDL200 is a novel endolysin-based anti- Clostridioides difficile causes an infection of the large intestine which is often referred to as C. difficile or C. diff. CDL200 showed potent and rapid activity against 100% clinical isolates from multi-nation and has no disturbance of the normal flora in human's gut. The potential clinical usage and indications are CDI and IBD (Inflammatory Bowel Disease), and the targeted administration route of CDL200 is oral in capsule formulation. CDL200 is under non-clinical stage development and IND enabling studies will be conducted throughout the year.
About iNtRON Biotechnology, Inc.
iNtRON is a leader in bacteriophage-based technology with aim to develop and investigate into the 'Immune & Immunotherapeutics' market. While pursuing global research and business development investments since their foundation and accelerated development after entering its IPO in KOSDAQ, the company honed in on innovating BIO New Drugs by developing various 'First-in-Concept' bio-drugs and conducting clinical studies in phases. The Company is committed to development of innovative innovation in the infectious diseases and 'Immune & Immunotherapeutics' area.
About iNtODEWORLD, Inc.
iNtRON has established its wholly owned US subsidiary, iNtODEWORLD, Inc. in 2017. iNtODEWORLD was initially registered in Delaware and the headquarter office is currently located in Boston. iNtODEWORLD provides news, updates and platform development progresses of iNtRON to its potential global partners and collaborators along with its own R&BD works in the US.
Orion Biotechnology | July 15, 2022
Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
The collaboration will combine the capabilities of Peptilogics’ AI platform (NautilusTM) with Orion Biotechnology’s proprietary drug discovery platform. The companies will leverage expertise in peptide design and engineering to drive drug discovery against an undrugged peptidergic GPCR linked to highly prevalent, life-threatening diseases.
Peptilogics’ Nautilus™ platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and custom-design therapeutics. Additionally, Peptilogics’ supercomputer accelerates model development, prediction and evaluation of peptide sequences to produce higher quality hits with greater chance of success. Synergistically, Orion Biotechnology’s platform explores receptor-ligand shape space using proprietary multiplex synthesis technology to generate precision-engineered peptides with enhanced potency and tailored signaling activity. Orion’s platform generates data matrices for AI-assisted lead optimization, offering one of the fastest drug discovery and development solutions to target peptidergic GPCRs.
On the announcement of this collaboration, Dr. Oliver Hartley, VP Drug Discovery at Orion Biotechnology, commented, “We are pleased to be partnering with Peptilogics to push the boundaries of receptor pharmacology and AI computing to accelerate innovation for improved patient outcomes. An AI-driven paradigm shift is happening in drug discovery, and Orion is pleased to be at the forefront of applying AI to the highly valuable space around GPCRs. The ideal fit between Orion’s platform and unique knowledge of receptor-ligand interactions with Peptilogics’ machine learning models will position us to make AI-driven GPCR drug discovery a reality.”
“Using Peptilogics’ Nautilus™ platform, we combine proprietary deep generative models, predictive models and biophysical simulation to design multiparameter-optimized peptides that have the potential to address historically challenging and novel drug targets. Our AI algorithms enable efficient navigation of the vast peptide design space, allowing us to uncover molecules that may not be discovered through traditional screening. We are excited to partner with Orion Biotechnology for their deep GPCR expertise. By combining the strengths of Peptilogics’ Nautilus™ AI-driven peptide design platform and Orion’s GPCR platform, we aim to reduce the risk, time and cost for drug design.”
Nicholas Nystrom, Ph.D., Chief Technology Officer of Peptilogics
About Orion Biotechnology
Orion Biotechnology Canada Ltd. is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs). Orion’s world-renowned experts in GPCR pharmacology and peptide/protein engineering leverage Orion’s proprietary drug discovery platform to rapidly and efficiently advance a diversified portfolio of precision engineered GPCR-targeted therapeutic candidates for the treatment of cancer and other serious diseases.
Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation.
GRAIL | June 06, 2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies. The collaboration will initially focus on developing companion diagnostic tests to identify patients with high-risk, early-stage disease, with plans to embark on numerous studies across multiple indications over the next several years. The parties are additionally planning to use GRAIL’s technology to enable recruitment of patients with early-stage cancer for AstraZeneca’s clinical studies.
GRAIL has developed a novel approach to detect cancer signals in blood, regardless of whether or not the patient has clinical symptoms. We are excited to embark on this work with AstraZeneca to transform cancer outcomes through a broad, strategic collaboration, Through our collaboration, we hope to provide critical information to improve the identification of patients who may be eligible for clinical trials and change clinical paradigms for the treatment of early-stage cancers."
Sir Harpal Kumar, President, Biopharma Business and Europe at GRAIL.
Across the projects within this collaboration, GRAIL will use its methylation platform to perform testing for patients enrolled in AstraZeneca’s clinical trials. GRAIL will seek regulatory approval in key markets for the liquid biopsy companion diagnostics.
Identifying and treating cancer early is at the heart of this strategic collaboration. Combining GRAIL’s innovative blood-based methylation profiling platform with AstraZeneca’s leadership in Oncology, we hope to accelerate the adoption of circulating tumor DNA across clinical trials and make our cancer medicines available at an earlier stage of disease when there is greater potential to transform patient outcomes, and even cure.”
Susan Galbraith, Executive Vice President of Oncology R&D, AstraZeneca.
GRAIL is developing its proprietary methylation platform for use in multiple post-diagnostic settings to identify patients at high risk of future cancer recurrence, detect the presence or absence of residual disease, and to inform treatment decisions, including identifying patients with cancer who may be eligible for neoadjuvant or adjuvant therapy. GRAIL’s technology platform is designed to optimize circulating tumor DNA testing to enable detection of early stage disease and minimal residual disease (MRD).
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021.